hackint0sh/New-Dataset huggingface dataset:
Upadacitinib is an approved drug for the treatment of moderate to severe atopic dermatitis (AD). This study is conducted in 2 periods. During Period 1, participants are randomly assigned into 1 of 2 groups called treatment arms to receive upadacitinib Dose A or dupilumab Dose A. Based on the participants response to upadacitinib Dose A, they may have their dose increased to upadacitinib Dose B after 2 weeks. In Period 2, participants that completed Period 1 will either remain on their assigned dose or be reassigned to a different dose based on their Eczema Area and Severity Index (EASI) response. Approximately 300 adult participants ages 18 to 64 with moderate to severe AD who are current users of dupilumab and had a history of inadequate response to dupilumab will be enrolled at up to 94 sites worldwide.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires. conditions: Atopic Dermatitis studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 300 type: ESTIMATED name: Upadacitinib Dose A name: Dupilumab Dose A name: Upadacitinib Dose B measure: Participants who achieve a composite endpoint of both a 90% reduction in Eczema Area and Severity Index from Baseline (EASI 90) and Worst Pruritus Numerical Rating Scale of 0 or 1 (WP-NRS 0/1) measure: Percentage of participants who achieve EASI 90 measure: Percentage of participants achieving worst pruritus numerical rating scale (WP-NRS) 0/1 measure: Percentage of participants achieving worst pruritus numerical rating scale (WP-NRS) 0/1 sex: ALL minimumAge: 18 Years maximumAge: 63 Years stdAges: ADULT hasResults: False
nctId: NCT06389123 id: 1788760 briefTitle: Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas overallStatus: RECRUITING date: 2024-04-01 date: 2027-03-31 date: 2028-03-31 date: 2024-04-29 date: 2024-04-29 name: University of California, Davis class: OTHER name: National Institutes of Health (NIH) briefSummary: This is a Phase I study to evaluate the safety and efficacy of the \[68Ga\]Ga DOTA-5G and \[177Lu\]Lu DOTA-ABM-5G theranostics pair in patients with metastatic cancer. conditions: Metastatic Cancer studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Single treatment primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G. measure: [68Ga]Ga DOTA-5G PET/CT imaging measure: [177Lu]Lu DOTA-ABM-5G treatment measure: [177Lu]Lu DOTA-ABM-5G treatment efficacy sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The University of California Davis Comprehensive Cancer Center status: RECRUITING city: Sacramento state: California zip: 95817 country: United States name: Julie L Sutcliffe, PhD role: CONTACT phone: 916-734-5536 email: jlsutcliffe@ucdavis.edu lat: 38.58157 lon: -121.4944 hasResults: False
nctId: NCT06389110 id: SOPH201-1023/III briefTitle: Study to Evaluate the Efficacy of Alleance® (Atropine Sulfate 0.01%) as a Treatment to Delay Myopia and Axial Ocular Elongation in Children. overallStatus: NOT_YET_RECRUITING date: 2024-12-30 date: 2027-06-30 date: 2027-06-30 date: 2024-04-29 date: 2024-04-29 name: Laboratorios Sophia S.A de C.V. class: INDUSTRY briefSummary: Phase III clinical study to evaluate the efficacy of Alleance® (atropine sulfate 0.01%) ophthalmic solution through the incidence of unexpected adverse events, changes in Best Corrected Visual Acuity (BCVA), changes in intraocular pressure, changes in the amplitude of accommodation, compared to placebo, as a treatment to delay the progression of myopia and axial ocular elongation in children. conditions: Myopia conditions: Myopia, Progressive studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This is a study to demonstrate superiority, double-blind, randomized, controlled, comparative, and multicenter phase III clinical trial. primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 123 type: ESTIMATED name: Alleance® name: Placebo measure: Changes in the spherical equivalent measure: Changes in axial eye length measure: Incidence of unexpected adverse events related to the interventions measure: Incidence of photophobia between interventions measure: Changes in pupillary diameter between the interventions measure: Changes in Best Corrected Visual Acuity (BCVA) measure: Changes in near best-corrected visual acuity measure: Changes in the amplitude of accommodation (AA) between interventions measure: Changes in intraocular pressure (IOP) sex: ALL minimumAge: 3 Years maximumAge: 12 Years stdAges: CHILD hasResults: False
nctId: NCT06389097 id: J23152 id: IRB00411454 type: OTHER domain: JHM IRB id: P01CA272222 type: NIH link: https://reporter.nih.gov/quickSearch/P01CA272222 briefTitle: SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization acronym: (SEEtoTREAT) overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2028-05 date: 2029-05 date: 2024-04-29 date: 2024-04-29 name: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins class: OTHER name: National Cancer Institute (NCI) briefSummary: The investigators will study SPECT imaging of radiopharmaceutical therapies given as standard of care or as part of other compatible research protocols. The goal is to validate the quantitative SPECT image reconstruction methods developed in this proposal, and to investigate the relation between dosimetry calculated from SPECT images and the outcomes. Patients will be recruited for SPECT/CT imaging during treatment. This is an observational study no additional new drugs or activities will be administrated. The investigators will perform SPECT imaging on a total of 80 patients (\~20 each from year 2 to year 5). Each participant will be imaged 3 times after the first and last cycles of planned radiopharmaceutical therapy. conditions: Prostate Cancer conditions: Advanced Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 80 type: ESTIMATED name: Radium-223 name: 177Lu-DOTATATE name: 177Lu-PSMA-617 measure: Mean absorbed dose to normal organs compared using different quantitative methods measure: Variability of intra-patient and inter-patient mean absorbed dose to normal organs compared using SPECT images measure: Mean absorbed dose to normal organs correlated with toxicity sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06389084 id: 179939 briefTitle: Parents Together: Supporting Parents to Promote Healthy Behaviours in Children overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2025-03-31 date: 2025-12-31 date: 2024-04-29 date: 2024-04-29 name: The Hospital for Sick Children class: OTHER briefSummary: The Parents Together trial aims to determine if the Parents Together program consisting of virtual parent group sessions and coaching calls, will result in better health outcomes for children. The program which is facilitated by a Public Health Nurse seeks to encourage healthy lifestyle behaviours, help build strong family relationships, and promote child development and mental health. conditions: Child Eating Behaviours conditions: Child Nutrition conditions: Early Child Development conditions: Parenting studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized control trial primaryPurpose: PREVENTION masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 128 type: ESTIMATED name: Parents Together parenting course measure: Child eating behaviours measure: Dietary intake and food environment measure: Nutritional risk measure: Physical Activity, Sedentary Time, Sleep Duration measure: Physical activity measure: Social and emotional development measure: Child development measure: Family psychosocial health measure: Parenting measure: Parenting sense of competence measure: sociodemographic, maternal and child characteristics measure: zBMI measure: Waist circumference measure: Blood pressure sex: ALL minimumAge: 2 Years maximumAge: 5 Years stdAges: CHILD facility: The Hospital for Sick Children city: Toronto state: Ontario country: Canada lat: 43.70011 lon: -79.4163 hasResults: False
nctId: NCT06389071 id: PLS001 briefTitle: Laser Treatment for Lichen Sclerosus overallStatus: RECRUITING date: 2024-03-01 date: 2025-12-20 date: 2025-12-30 date: 2024-04-29 date: 2024-04-29 name: Sciton class: INDUSTRY briefSummary: Fractional ablative laser treatment for Lichen Sclerosus lesion conditions: Lichen Sclerosus Lesion studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 50 type: ESTIMATED name: Fractional 2940 nm Laser measure: Histological clearance sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Clinique Medicale Uro-Gyneco de l'Abitibi status: RECRUITING city: Val-d'Or state: Quebec zip: J9P1W1 country: Canada name: Josee Parent, MD role: CONTACT phone: 819-825-3800 lat: 48.0974 lon: -77.79737 hasResults: False
nctId: NCT06389058 id: G00014538 briefTitle: Using NLP and Neural Networks to Autonomously Identify Severe Asthma and Determine Study Eligibility in a Large Healthcare System overallStatus: ACTIVE_NOT_RECRUITING date: 2023-05-01 date: 2024-07-01 date: 2026-11 date: 2024-04-29 date: 2024-04-29 name: San Diego State University class: OTHER name: GlaxoSmithKline name: Scripps Health name: Modena Allergy + Asthma, La Jolla, CA name: University of California, San Diego briefSummary: The study aims to to use new technologies (ML, AI, NLP), to autonomously identify moderate to severe asthma populations within an EHR system, describe differences in treatment patterns across different populations, and determine trial eligibility.
* Aim 1c: Use a combination of ML applied to structured data to predict SA. Determine model accuracy as above in Aim 1a. conditions: Severe Asthma studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 31795 type: ACTUAL name: Recommendation for the diagnoses and treatment of Severe Athma measure: Identification of Patients with Severe Asthma sex: ALL minimumAge: 6 Years maximumAge: 85 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: San Diego State University city: San Diego state: California zip: 92182-1309 country: United States lat: 32.71533 lon: -117.15726 hasResults: False
nctId: NCT06389045 id: EUS briefTitle: Profopol and Remifentanil Sedation in Endoscopic Ultrasonography overallStatus: RECRUITING date: 2024-04-24 date: 2024-06-24 date: 2024-07-01 date: 2024-04-29 date: 2024-04-29 name: Samsun University class: OTHER briefSummary: Endoscopic ultrasonography (EUS) is an endoscopic procedure performed to investigate conditions affecting the stomach, liver, and bile ducts, as well as for therapeutic interventions. The complexity of EUS can vary significantly, with increased complexity affecting procedure duration, technical success, and the occurrence of adverse events. For the comfort of patients and the success of the procedure, these interventions are typically performed under anesthesia with procedural sedation. To enhance the success rate of the procedure, reduce the risk of side effects, and maximize patient comfort, EUS is generally performed under sedation according to the recommendations of the American Society of Anesthesiologists (ASA). During sedation, the aim is for the patient to be more relaxed and comfortable while maintaining spontaneous respiratory function. Preserving spontaneous respiratory parameters is crucial for procedural safety. conditions: Sedation Complication conditions: Endoscopic Ultrasonography conditions: Procedural Sedation studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 70 type: ESTIMATED name: Procedural Sedation measure: Anesthesia related major complications measure: The prevalence of symptoms of inadequate sedation sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Samsun University Faculty of Medicine status: RECRUITING city: Samsun country: Turkey name: Caner Genc, M.D. role: CONTACT phone: 5444846865 phoneExt: +90 email: dr.canergenc@gmail.com lat: 41.27976 lon: 36.3361 hasResults: False
nctId: NCT06389032 id: 21041503 id: 1R01AG079128-01A1 type: NIH link: https://reporter.nih.gov/quickSearch/1R01AG079128-01A1 briefTitle: PERSEVERE in Lewy Body Dementia: A Randomized, Controlled Trial of Peer Mentor Support and Caregiver Education overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2027-10-15 date: 2028-06-30 date: 2024-04-29 date: 2024-04-29 name: Rush University Medical Center class: OTHER name: National Institute on Aging (NIA) briefSummary: Lewy Body Dementia (LBD) is the second most common form of degenerative dementia, affecting at least 2.4 million US adults, and the overwhelming majority of persons living with LBD (PLBD) are cared for by family caregivers. LBD caregiver strain: 1) exceeds that of non-LBD dementia caregivers; 2) worsens caregiver physical and mental health; and 3) increases the risk of PLBD hospitalization and institutionalization. LBD progression is complicated by combined motor, cognitive, and neuropsychiatric decline, and is punctuated by falls, infections, dehydration, and neuropsychiatric symptoms leading to acute healthcare utilization. Although family caregivers are uniquely positioned to identify and manage these challenges, which may avert emergency department visits and reduce morbidity, many caregivers lack the knowledge, skills, confidence, resources, and support to do so.
We aim to 1) quantify the impact of PERSEVERE on caregiver knowledge, attitudes, mastery, and strain; 2) identify the intervention and mentor factors determining implementation fidelity; and 3) test the effects of PERSEVERE on PLBD quality of life and healthcare utilization. This will be accomplished in an NIH Behavioral Model Stage II national, randomized, attention-controlled, 12-week trial of PERSEVERE in 502 LBD caregivers in partnership with the Lewy Body Dementia Association, Parkinson's Foundation, and LBD Caregiver Advisors. We will match intervention arm caregivers with a trained peer mentor who will coach them through a modular, theory-based curriculum on LBD knowledge and social support. Attention-control participants will receive weekly, curated links to educational materials. We will identify immediate and delayed intervention effects, including mediators of strain at 12 weeks, and caregiver strain and PLBD outcomes at nine months. Implementation fidelity and PLBD healthcare utilization will be tracked biweekly. Qualitative methods will explore the intervention- and mentor-specific factors predicting fidelity, mentee outcomes, and retention. Remote recruitment, mentoring, and community engagement strategies will maximize accessibility and inclusion of underrepresented caregiver groups. Results will illuminate the extent to which leveraging prior LBD caregivers as expert interventionists can improve current caregiver outcomes, and in turn, PLBD outcomes. These results will inform future adaptation and dissemination of this model for other conditions. conditions: Lewy Body Dementia conditions: Parkinson Disease Dementia conditions: Dementia With Lewy Bodies conditions: Lewy Body Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 622 type: ESTIMATED name: Peer Mentor Support and Caregiver Education name: Caregiver Education measure: Multidimensional Caregiver Strain Index (MCSI) measure: Quality of Life in Alzheimer's Disease ( QoL-AD) measure: Dementia Attitudes Scale (DAS) measure: LBD Knowledge Test ( LBDK) measure: Baseline PLBD Fall Frequency and Healthcare Utilization Questionnaire measure: Fortinsky Caregiver Self-Efficacy Score measure: Multidimensional Scale of Perceived Social Support (MSPSS) measure: Pearlin Mastery Scale measure: Frequency and Duration of Mentoring Calls measure: Study adherence of Mentors and Mentees measure: Coverage of target topics; additional topics discussed sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Rush University Medical Center city: Chicago state: Illinois zip: 60612 country: United States name: Persevere Study Team role: CONTACT phone: 312-563-3300 email: persevere@rush.edu name: Dr. Jori Fleisher, MD MSCE role: PRINCIPAL_INVESTIGATOR lat: 41.85003 lon: -87.65005 hasResults: False
nctId: NCT06389019 id: BLCA_CMUFH id: K2024-187-01 type: OTHER domain: The First Affiliated Hospital of Chongqing Medical University briefTitle: Whole-slide Image and CT Radiomics Based Deep Learning System for Prognostication Prediction in Bladder Cancer overallStatus: RECRUITING date: 2024-01-01 date: 2024-06-01 date: 2024-10-01 date: 2024-04-29 date: 2024-04-29 name: Mingzhao Xiao class: OTHER briefSummary: Bladder cancer (BLCA), with its diverse histopathological features and varying patient outcomes, poses significant challenges in diagnosis and prognosis. Postoperative survival stratification based on radiomics feature and whole slide image feature may be useful for treatment decisions to improve prognosis. In this research, we aim to develop a deep learning-based prognostic-stratification system for automatic prediction of overall and cancer-specific survival in patients with BLCA. conditions: Bladder Cancer studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: RETROSPECTIVE count: 1000 type: ESTIMATED name: Deep learning system for prognostication prediction in bladder cancer measure: Overall survival measure: Recurrence free survival sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Urology, The First Affiliated Hospital of Chongqing Medical University status: RECRUITING city: Chongqing state: Chongqing zip: 400016 country: China name: QuanHao He, PHD role: CONTACT phone: 800-555-5555 email: 2020120460@stu.cqmu.edu.cn name: Mingzhao Xiao, PHD role: CONTACT phone: 023-89012557 email: 2023140134@stu.cqmu.edu.cn lat: 29.56278 lon: 106.55278 hasResults: False
nctId: NCT06389006 id: RC48-C025 briefTitle: To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2025-06-01 date: 2026-12-31 date: 2024-04-29 date: 2024-04-29 name: RemeGen Co., Ltd. class: INDUSTRY briefSummary: The purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin combined with Toripalimab sequential chemotherapy as in patients with HR-positive, HER2-low breast cancer conditions: HR-positive, HER2-low Breast Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 79 type: ESTIMATED name: Disitamab Vedotin for Injection name: Toripalimab name: Epirubicin name: Cyclophosphamide measure: Total pathological complete response (tpCR) rate measure: Breast pathological complete response（bpCR） measure: Event free survival (EFS) measure: Disease-free survival (DFS) measure: Objective Response Rate (ORR) measure: Adverse events (AEs) measure: Change in cluster of differentiation 8 (CD8) measure: Health-related quality of life - EORTC-QLQ-C30 measure: Residual cancer burden score measure: Change in tumor-infiltrating lymphocytes (TILs) measure: Change in programmed cell death protein L1 (PD-L1) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Jiong Wu city: Shanghai state: Fudan University Shanghai Cancer Center zip: 200032 country: China name: Jiong Wu, Ph.D role: CONTACT lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06388980 id: UFCIN1_2022 briefTitle: Knowledge and Needs of Nursing in Relation to the Treatment Complex Wounds overallStatus: ACTIVE_NOT_RECRUITING date: 2023-05-01 date: 2023-06-01 date: 2024-06-01 date: 2024-04-29 date: 2024-04-29 name: Corporacion Parc Tauli class: OTHER briefSummary: Study with cross-sectional and descriptive mixed methodology. With questionnaires with likert-type questions (0-10) being the 10 with the highest score, and open questions in relation to knowledge in wound care; include all Corporaciló Sanitària Parc Taulí (CCSPT) nurses who voluntarily want to participate in a pseudo-anonymized surv conditions: Nurse's Role conditions: Knowledge, Attitudes, Practice conditions: Wound studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 200 type: ESTIMATED name: Validated questionnaires and ad hoc questions measure: "What not to do in chronic wounds?" measure: ReAc-PUKT (Renobato-Acosta Pressure Ulcer Knowledge Test) measure: Ad hoc open questions sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Corporació Sanitària Parc Taulí city: Sabadell state: Barcelona zip: 08208 country: Spain lat: 41.54329 lon: 2.10942 hasResults: False
nctId: NCT06388954 id: P.T.REC/012/005107 briefTitle: Plasticity Biomarkers,Interleukin-6 and Motor Performance in Response to Vagus Nerve Stimulation After Stroke overallStatus: RECRUITING date: 2024-02-21 date: 2024-04-23 date: 2024-05-09 date: 2024-04-29 date: 2024-04-29 name: Cairo University class: OTHER briefSummary: Forty-eight clinically verified Egyptian patients from both sexes with ischemic stroke that occurred at least 6 months to 2 years before inclusion will be randomly assigned into 2 groups, control group (GA) and the experimental group (GB). Patients will be randomly assigned into two equal groups: the control group (GA) and the experimental group (GB). Patients in the control group (GA) will be treated with sham Vagus nerve stimulation (taVNS) immediately before a selected physical therapy program, while in the experimental group (GB), patients will receive real transcutaneous auricular Vagus nerve stimulation (taVNS) followed by the same selected physical therapy program as (GA). Plasma level of Brain-Derived Neurotrophic Factors (BDNF) and Interleukin-6 (IL-6), Box and Blocks Test (BBT), and modified Ashworth scale (MAS) will be assessed at baseline and immediately post-treatment. conditions: Stroke conditions: Motor Disorders studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Single-blind, randomized controlled study. primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Patients participated will be masked about the type of intervention, where (GA) patients will receive physical therapy program + sham transcutaneous auricular Vagus nerve stimulation, while patients in (GB) will receive true transcutaneous auricular Vagus nerve stimulation in addition to the same physical therapy program as (GA). whoMasked: PARTICIPANT count: 50 type: ESTIMATED name: True Transcutaneous auricular Vagus Nerve Stimulation (TaVNS) name: Sham Trancutaneous auricular Vagus Nerve Stimulation measure: Muscle tone of the upper limb measure: Gross hand dexterity measure: Level of Plasma brain-derived Derived factor (BDNF) measure: Level of Serum Interleukin IL-6 sex: ALL minimumAge: 55 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Faculty of Physical Therapy, Cairo University status: RECRUITING city: Giza state: Ad Doqi, Giza District, Giza Governorate zip: 11432 country: Egypt name: Engy BadrEldin S Moustafa, PhD role: CONTACT phone: 00201099445112 email: engybm.saleh@cu.edu.eg name: Moshera H. Darwish, PhD role: CONTACT phone: 00201015163617 email: dr.moshera11@yahoo.com lat: 30.00808 lon: 31.21093 hasResults: False